![]() | |
Clinical data | |
---|---|
Trade names | Desernil, Sansert |
Other names | UML-491; 1-Methylmethylergonovine; N-[(2S)-1-Hydroxybutan-2-yl]-1,6-dimethyl-9,10-didehydroergoline-8α-carboxamide; N-(1-(Hydroxymethyl)propyl)-1-methyl-D-lysergamide |
AHFS/Drugs.com | International Drug Names |
MedlinePlus | a603022 |
Pregnancy category |
|
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.006.041 |
Chemical and physical data | |
Formula | C21H27N3O2 |
Molar mass | 353.466 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Methysergide, sold under the brand names Deseril and Sansert, is a monoaminergic medication of the ergoline and lysergamide groups which is used in the prophylaxis and treatment of migraine and cluster headaches.[2] It has been withdrawn from the market in the United States and Canada due to adverse effects.[3] It is taken by mouth.[3]
Methysergide is no longer recommended as a first line treatment protocol by international headache societies, hospitals, and neurologists in private practice, for migraines or cluster headaches as side effects were first reported with long-term use in the late 1960s, and ergot-based treatments fell out of favor for the treatment of migraines with the introduction of triptans in the 1980s.
pmid23815106
was invoked but never defined (see the help page).